Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 4 Colorectal Neoplasms 4 Recurrence 3 Carcinoma, Non-Small-Cell Lung 3 Small Cell Lung Carcinoma 2 Radiation Pneumonitis 2 Prostatic Neoplasms 2 Mesothelioma, Malignant 2 Lung Neoplasms 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Ovarian Diseases 1 Oligodendroglioma 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphangioleiomyomatosis 1 Leukemia, Myeloid, Acute 1 Inflammatory Breast Neoplasms 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Esophagogastric Adenocarcinoma 1 Endometrial Neoplasms 1

Interventions

Oxaliplatin 67 Capecitabine 60 Fluorouracil 58 Bevacizumab 54 Gemcitabine 51 Paclitaxel 50 Leucovorin 50 Irinotecan 40 Docetaxel 39 Carboplatin 39 Cisplatin 38 pembrolizumab 37 Nivolumab 37 Cetuximab 35 Sunitinib 25 Trastuzumab 24 Radiosurgery 24 Radiotherapy 21 Doxorubicin 21 Cyclophosphamide 21 Panitumumab 20 Drug Therapy 19 Pemetrexed 18 Everolimus 18 Sorafenib 17 Interleukin-2 16 Fulvestrant 16 Albumin-Bound Paclitaxel 16 atezolizumab 15 Erlotinib Hydrochloride 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm Metastasis × nintedanib × Clear all

NCT02856867 2017-05-09

MEGAN

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡